PAR

5.00%

19.0¢ paradigm biopharmaceuticals limited..

NOTES on AGM 2020, page-4

First 4 Last

Share
Profile

Follow
Nickporthcawl

1,542 Posts.

193

19/11/20

23:46

Post #: 49005324
Share

Originally posted by Eire2011: ↑

Awesome report Mozz and thank you. Capital 51 released a podcast tonight that discusses the importance of the FDA feedback and how this may impact the Pay for use SAS program.

The other nugget I got was the comment (and I need to listen back once the recording is available) that MPS may be partnered earlier ie on phase 2 results while we focus on the main event. Even went so far as to suggest BioMarin who we now have links with.

Again, thanks for the report. The main takeaways for me where:

* We have so much going on that we require a 2 day R&D event to go through it all properly. This will likely uncover new indications that we are not aware of.
* Partnering for MPS could be earlier than OA
* We may become revenue generating earlier than we all thought, opening the door to more long only funds.
* The conference presentations will likely increase the growing overseas interest.
* There are exciting plans in the wind to do more JV’s with Bene, even involving building manufacturing together if we are successful.
* The FDA feedback is critical for so many reasons and a lot of our next moves depend on it. Essentially the feedback from this meeting could determine whether we need any further CR or not.
* We have already had unsolicited offers
* Paul is working hard to protect the company from a premature / forced takeover.
* That I need to eat humble pie as the questions we asked were the best ones and answered so much more candidly and in detail that I expected.

Thanks again to Mozz and to the excellent (and rare) PAR HC community.

Expand

Great posts Mozz and Eire. Excellent writing style

I belief the R&D is a one day event either the 21 or 22 Dec

Absolutely agree that Paul knows what we have and will maximise SH returns

PAR Price at posting: $3.05 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

The winners & losers on market if negative gearing were gone

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

There are more pages in this discussion • 44 more messages in this thread...

First 4 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change -0.010(5.00%)		Mkt cap ! $66.54M

Open	High	Low	Value	Volume
20.0¢	21.0¢	19.0¢	$203.4K	1.019M

Buyers (Bids)

No.	Vol.	Price($)
14	387930	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
20.5¢	65468	2

View Market Depth

No.	Vol.	Price($)
14	387930	0.190
3	57000	0.185
10	205428	0.180
6	140904	0.175
8	615605	0.170

Price($)	Vol.	No.
0.205	65468	2
0.210	28079	4
0.215	30000	1
0.220	27066	4
0.225	21604	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

PAR (ASX) Chart

NOTES on AGM 2020, page-4

The market's shrugged at China's stimulus measures all year. Why is this one different?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Zeta Resources seeks to resolve the Panoramic takeover story

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

NOTES on AGM 2020, page-4

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Zeta Resources seeks to resolve the Panoramic takeover story

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News